Tapentadol in Chronic Malignant Tumour Related Pain
Status:
Terminated
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is the characterization of the long term safety profile and
long-term dose requirements of tapentadol PR (prolonged release) in patients with malignant
tumor-related pain. In the United States the prolonged-release formulation is also referred
to as the extended-release formulation.